Lineage Cell Therapeutics, Inc.
LCTX
$0.485
-$0.015-3.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.50M | 8.72M | 6.19M | 8.00M | 8.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.50M | 8.72M | 6.19M | 8.00M | 8.95M |
| Cost of Revenue | 12.81M | 13.39M | 14.09M | 15.18M | 16.38M |
| Gross Profit | -3.31M | -4.67M | -7.91M | -7.18M | -7.43M |
| SG&A Expenses | 18.17M | 14.53M | 14.16M | 14.05M | 13.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.98M | 27.92M | 28.25M | 29.23M | 30.15M |
| Operating Income | -21.48M | -19.20M | -22.07M | -21.22M | -21.20M |
| Income Before Tax | -18.58M | -20.05M | -24.20M | -23.63M | -23.28M |
| Income Tax Expenses | -- | 0.00 | 0.00 | 0.00 | -1.80M |
| Earnings from Continuing Operations | -18.58 | -20.05 | -24.20 | -23.63 | -21.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.00K | -65.00K | 16.00K | -23.00K | -7.00K |
| Net Income | -18.61M | -20.11M | -24.19M | -23.66M | -21.49M |
| EBIT | -21.48M | -19.20M | -22.07M | -21.22M | -21.20M |
| EBITDA | -20.87M | -18.57M | -21.40M | -20.53M | -20.51M |
| EPS Basic | -0.10 | -0.11 | -0.13 | -0.13 | -0.12 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.07 | -0.07 | -0.07 |
| EPS Diluted | -0.10 | -0.11 | -0.13 | -0.13 | -0.12 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.07 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 800.75M | 735.57M | 721.60M | 703.38M | 690.60M |
| Average Diluted Shares Outstanding | 800.75M | 735.57M | 721.60M | 703.38M | 690.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
